JNPMEDI and Avance Clinical Sign MOU to Strengthen Global Clinical Trial Competitiveness.

JNPMEDI, a Medical data platform company, announced on the 1st that it has signed a Memorandum of Understanding (MOU) with Avance Clinical, a global Contract Research Organization (CRO) based in Australia, aimed at enhancing mutual business competitiveness.

Avance Clinical is recognized as a global full-service CRO with 26 years of experience providing high-quality clinical trial services to global biotechs through its highly specialized personnel, advanced technology, and expertise across Australia, New Zealand, and North America.

This MOU establishes a collaborative framework between two companies, aimed at strengthening the competitiveness of global clinical trial services based on their respective expertise and capabilities. By integrating Avance Clinical’s extensive global network and full-service CRO capabilities with the technological infrastructure of JNPMEDI’s medical data platform, ‘Maven Clinical Cloud,’ the partnership is poised to amplify their global clinical trial competitiveness through mutual synergy.

In particular, the plan is to maximize the synergy between the two companies by focusing on marketing targeting pharmaceutical and biotech companies seeking to conduct early clinical trials in Australia for entry into advanced markets such as the United States or Europe.

Jaehyun (Jay) Lee, director of JNPMEDI, stated, “This MOU will be an opportunity for both companies to enhance their business competitiveness not only in Australia, but also in the global market by combining their strengths,” adding, “We will strive to establish mutual growth momentum through close cooperation.”

Avance Clinical CEO, Yvonne Lungershausen, expressed her pleasure at collaborating with JNPMEDI, which is producing excellent results based on outstanding technical capabilities, for global market expansion. She said, “I look forward to expanding business opportunities through organic collaboration that maximizes synergy between the two companies.”